Lycera Announces Initiation of Phase 1 Clinical Trial of Experimental Inflammatory Bowel Disease Therapy

Lycera Announces Initiation of Phase 1 Clinical Trial of Experimental Inflammatory Bowel Disease Therapy
Lycera Corp., a biopharmaceutical company that develops novel oral immune modulators to treat autoimmune conditions and cancer, recently announced the start of a new Phase 1 clinical study of its experimental LYC-30937 therapy in a population of healthy volunteers. LYC-30937, an oral ATPase modulator that targets the gut, is being evaluated to treat inflammatory bowel disease (IBD).

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *